vorinostat has been researched along with HIV in 5 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Demethylation of H3K27 mediated by the histone methyltransferase inhibitor GSK343 in primary resting T cells is slow, occurring over 96 h, but by itself does not result in a significant upregulation of cell-associated HIV RNA expression or viral antigen production." | 7.81 | H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells. ( Archin, NM; Burch, BD; Margolis, DM; McManamy, ME; Tripathy, MK, 2015) |
| "Demethylation of H3K27 mediated by the histone methyltransferase inhibitor GSK343 in primary resting T cells is slow, occurring over 96 h, but by itself does not result in a significant upregulation of cell-associated HIV RNA expression or viral antigen production." | 3.81 | H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells. ( Archin, NM; Burch, BD; Margolis, DM; McManamy, ME; Tripathy, MK, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tripathy, MK | 1 |
| McManamy, ME | 1 |
| Burch, BD | 1 |
| Archin, NM | 1 |
| Margolis, DM | 2 |
| White, CH | 1 |
| Johnston, HE | 1 |
| Moesker, B | 1 |
| Manousopoulou, A | 1 |
| Richman, DD | 1 |
| Spina, CA | 1 |
| Garbis, SD | 1 |
| Woelk, CH | 1 |
| Beliakova-Bethell, N | 1 |
| Ke, R | 1 |
| Lewin, SR | 1 |
| Elliott, JH | 1 |
| Perelson, AS | 1 |
| Contreras, X | 1 |
| Schweneker, M | 1 |
| Chen, CS | 1 |
| McCune, JM | 1 |
| Deeks, SG | 1 |
| Martin, J | 1 |
| Peterlin, BM | 1 |
| Friedrich, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Research In Viral Eradication of HIV Reservoirs[NCT02336074] | Phase 2 | 60 participants (Actual) | Interventional | 2015-11-27 | Completed | ||
| IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)[NCT02707900] | Phase 1 | 6 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Histone H4 acetylation using a H4K5/8/12/16 immunoassay with thawed PBMC derived cell lysates added to an ELISA using anti-H4 monoclonal antibody (NCT02336074)
Timeframe: 12 weeks
| Intervention | Fold increase pre to post vorinostat (Mean) |
|---|---|
| Intervention (Arm B - ART + Vaccines + Vorinostat) | 3.19 |
Number of Participants with undetectable quantitative viral outgrowth (NCT02336074)
Timeframe: At week 16
| Intervention | Participants with undetectable outgrowth (Number) |
|---|---|
| Control (Arm A - ART Only) | 12 |
| Intervention (Arm B - ART + Vaccines + Vorinostat) | 6 |
The average of two measures taken at post-randomisation week 16 and 18 (NCT02336074)
Timeframe: Averaged across post-randomisation week 16 and 18
| Intervention | HIV-DNA copies/mill CD4+ T cells (log10) (Mean) |
|---|---|
| Control (Arm A - ART Only) | 2.95 |
| Intervention (Arm B - ART + Vaccines + Vorinostat) | 3.06 |
"CD8+ T cell antiviral suppressive activity was expressed as percentage elimination and determined as follows: [(fraction of p24+ cells in CD4+ T cells cultured alone) - (fraction of p24 + in CD4+ T cells cultured with CD8+ cells)]/(fraction of p24+ cells in CD4+ T cells cultured alone) × 100.~Viral inhibition Assay" (NCT02336074)
Timeframe: 12 weeks
| Intervention | Percentage elimination (Mean) |
|---|---|
| Control (Arm A - ART Only) | -18.25 |
| Intervention (Arm B - ART + Vaccines + Vorinostat) | 1.50 |
Percentage of CD8+ CD107a+ IFNγ+ T cells , assessed using an optimized and qualified flow cytometry panel. (NCT02336074)
Timeframe: 12 weeks
| Intervention | % cells CD8+ CD107a+ IFNγ+ (Median) | |
|---|---|---|
| Post randomisation week 9 | Post randomisation week 12 | |
| Control (Arm A - ART Only) | 0.052 | 0.062 |
| Intervention (Arm B - ART + Vaccines + Vorinostat) | 0.194 | 0.263 |
Percentage of CD4+ CD154+ IFNγ+ T cells , assessed using an optimized and qualified flow cytometry panel. (NCT02336074)
Timeframe: 12 weeks
| Intervention | % cells CD4+ CD154+ IFNγ+ (Median) | |
|---|---|---|
| Post randomisation week 9 | Post randomisation week 12 | |
| Control (Arm A - ART Only) | 0.006 | 0.006 |
| Intervention (Arm B - ART + Vaccines + Vorinostat) | 0.097 | 0.109 |
5 other studies available for vorinostat and HIV
| Article | Year |
|---|---|
H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.
Topics: Analysis of Variance; CD4-Positive T-Lymphocytes; Chromatin Immunoprecipitation; Enhancer of Zeste H | 2015 |
Mixed effects of suberoylanilide hydroxamic acid (SAHA) on the host transcriptome and proteome and their implications for HIV reactivation from latency.
Topics: CD4-Positive T-Lymphocytes; Cells, Cultured; Chromatography, Liquid; Gene Expression Profiling; HIV; | 2015 |
Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells.
Topics: Histone Deacetylase Inhibitors; HIV; Humans; Hydroxamic Acids; Transcriptional Activation; Virus Lat | 2015 |
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.
Topics: Adult; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infections; Humans; Hydroxamic Acids; | 2009 |
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.
Topics: Adult; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infections; Humans; Hydroxamic Acids; | 2009 |
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.
Topics: Adult; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infections; Humans; Hydroxamic Acids; | 2009 |
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.
Topics: Adult; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infections; Humans; Hydroxamic Acids; | 2009 |
Scientists investigate routing latent HIV from its reservoirs to achieve a cure.
Topics: Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Clinical Trials as Topic; Histone Deacetylase In | 2012 |